FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Faga Daniel
2. Issuer Name and Ticker or Trading Symbol

ANAPTYSBIO, INC [ ANAB ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200
3. Date of Earliest Transaction (MM/DD/YYYY)

11/26/2021
(Street)

SAN DIEGO, CA 92121
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $31.12 11/26/2021  A   11000     (1)11/25/2031 Common Stock 11000 $0.00 11000 D  
Stock Option (Right to Buy) $31.12 11/26/2021  A   2321     (2)11/25/2031 Common Stock 2321 $0.00 2321 D  

Explanation of Responses:
(1) 1/36th of the total shares subject to the option shall vest on December 26, 2021 and 1/36th of the total shares subject to the option shall vest on each monthly anniversary thereafter, subject to the reporting person's continuous status as a director through each such date.
(2) The option shall vest and become exercisable in full on February 10, 2022, subject to the reporting person's continuous status as a director through February 10, 2022.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Faga Daniel
C/O ANAPTYSBIO, INC.
10421 PACIFIC CENTER COURT, SUITE 200
SAN DIEGO, CA 92121
X



Signatures
/s/ Eric Loumeau, Attorney-in-Fact11/30/2021
**Signature of Reporting PersonDate

AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more AnaptysBio Charts.
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more AnaptysBio Charts.